BOOK
Pharmacology and Pharmacotherapeutics - E-Book
RS Satoskar | Nirmala Rege | SD Bhandarkar
(2015)
Additional Information
Book Details
Abstract
A classic Pharmacology book trusted equally by students and practicing physicians for its up-to-date, accurate and reliable text, which has always placed before the readers an integrated approach intertwining current knowledge of pathophysiology of the disease, pharmacology of available drugs and strategies for medical management of diseases.
• Trusted Pharmacology book with emphasis on pathophysiology, clinical pharmacology and therapeutics, presenting information in integrated manner.
• Up-to-date information supplemented with tables and diagrams, having: - therapy of important diseases presented in boxes. - current guidelines to support therapeutic decisions - tips for practising physicians.
• Uses integrated approach intertwining current knowledge of pathophysiology of the disease, pharmacology of available drugs and strategies for medical management of diseases. • Balances the complexity and simplicity of scientific content to provide students of medicine and/or pharmacy an insight into rational therapeutics.
Table of Contents
| Section Title | Page | Action | Price |
|---|---|---|---|
| Front Cover\r | Cover | ||
| Pharmacology and Pharmacotherapeutics | i | ||
| Copyright Page | ii | ||
| Table of Contents | iii | ||
| Preface to the Twenty-fourth Edition | vii | ||
| Preface to the First Edition | ix | ||
| Some Abbreviations Used in the Text | xi | ||
| SECTION I: General Pharmacology | 1 | ||
| Chapter 1. General Considerations and Pharmacokinetics | 1 | ||
| The Nature and Sources of Drugs | 3 | ||
| Sources of Drug Information | 5 | ||
| Routes of Drug Administration and Dosage Forms | 6 | ||
| Absorption and Bioavailability | 11 | ||
| Distribution of a Drug | 15 | ||
| Fate of a Drug | 18 | ||
| Drug Excretion | 21 | ||
| Plasma Half-life and its Significance | 22 | ||
| Methods of Prolonging the Duration of Action of a Drug | 26 | ||
| Special Drug Delivery Systems | 26 | ||
| Chapter 2. Pharmacodynamics – Drug Receptor Interaction; Adverse Drug Reactions | 28 | ||
| Site of Drug Action | 28 | ||
| Structure Activity Relationship (SAR) | 29 | ||
| Mechanism of Drug Action | 30 | ||
| Drug Receptors | 32 | ||
| Dose Response Relationship | 37 | ||
| Adverse Drugs Reactions (ADR) | 41 | ||
| Drug Allergy | 43 | ||
| Manifestations of ADR | 45 | ||
| Treatment of Acute Drug Poisoning | 48 | ||
| Chapter 3. Principles of Drug Prescribing; Factors Modifying the Effects of a Drug; and Drug Interactions | 50 | ||
| Drug Prescribing | 50 | ||
| P-drug (Personal drug) Concept | 54 | ||
| Essential Drugs | 55 | ||
| Orphan Drugs | 55 | ||
| Factors Modifying the Effects of a Drug | 56 | ||
| Drug Interactions | 63 | ||
| Chapter 4. Drug Invention; New Drug Development; and Drug Assay | 68 | ||
| Animal Toxicity Studies | 69 | ||
| Clinical Evaluation | 71 | ||
| Drug Assay | 76 | ||
| SECTION II: Drugs Acting on the Central Nervous System | 80 | ||
| Chapter 5. General Considerations | 80 | ||
| Chapter 6. Aliphatic Alcohols | 87 | ||
| Acute Alcohol Intoxication | 91 | ||
| Chronic Alcoholism | 92 | ||
| Alcohol Dependence | 92 | ||
| Chapter 7. General Anaesthetics | 97 | ||
| Inhalational General Anaesthetics | 98 | ||
| Volatile Liquid Anaesthetics | 101 | ||
| Gaseous Anaesthetics | 103 | ||
| Non-Volatile General Anaesthetics | 104 | ||
| Neuroleptanalgesia | 107 | ||
| Pre-anaesthetic Medication | 109 | ||
| Drugs Administered During Anaesthesia | 110 | ||
| Chapter 8. Sedatives, Hypnotics and Pharmacotherapy of Sleep Disorders | 111 | ||
| Benzodiazepines | 113 | ||
| Non-benzodiazepine, Benzodiazepine-receptor Agonists | 116 | ||
| Barbiturates | 117 | ||
| Alcohols | 122 | ||
| Aldehydes | 122 | ||
| Melatonin Recepter Agonist | 122 | ||
| Orexin Receptor Antagonists | 123 | ||
| Miscellaneous | 123 | ||
| Pharmacotherapy of Insomnia and Other Sleep Disorders | 123 | ||
| Chapter 9. Drugs Effective in Seizure Disorders | 129 | ||
| Types of Epilepsy | 129 | ||
| Anti-epileptic Drugs (AED) | 132 | ||
| General Principles of Management of Epilepsy | 141 | ||
| Epilepsy and Pregnancy | 144 | ||
| Drug Therapy of Epilepsy | 144 | ||
| Chapter 10. Opioid Analgesics and Antagonists | 149 | ||
| Opium Alkaloids | 153 | ||
| Semisynthetic Derivatives of Natural Opium Alkaloids | 159 | ||
| Synthetic Morphine Substitutes | 160 | ||
| Opioid Antagonists | 164 | ||
| Chapter 11. Analgesic-Antipyretics and Nonsteroidal Anti-inflammatory Drugs (NSAIDs) | 167 | ||
| Salicylates | 170 | ||
| Para-Aminophenol Derivatives | 177 | ||
| Pyrazolone Derivatives | 177 | ||
| Indoles and Related Drugs | 178 | ||
| Heterocyclic Arylacetic Acid Derivatives | 178 | ||
| Propionic Acid Derivatives | 179 | ||
| Fenamates | 180 | ||
| Oxicams | 180 | ||
| Preferential and Selective COX-2 Inhibitors | 180 | ||
| Pharmacotherapy of Pain | 182 | ||
| NSAID and Renal Damage | 186 | ||
| Chapter 12. Central Nervous System Stimulants | 188 | ||
| Stimulants of the Brain Stem and Medullary Centres | 191 | ||
| Stimulants of the Spinal Cord | 192 | ||
| Reflex Stimulants of the Central Nevous System Nervous System | 192 | ||
| Chapter 13. Psychopharmacology - 1: Introduction, Antipsychotic Drugs and Pharmacotherapy of Major Psychotic Disorders | 193 | ||
| Antipsychotic Drugs | 195 | ||
| Atypical Antipsychotics (Second Generation) | 201 | ||
| Management of Schizophrenia | 203 | ||
| Manic Depressive Psychosis – Management | 205 | ||
| Chapter 14. Psychopharmacology - 2: Anxiolytics, Antidepressants and Mood Modifying Agents | 208 | ||
| Treatment of Anxiety Disorders | 209 | ||
| Antidepressant Drugs | 212 | ||
| Monoamine Oxidase Inhibitors (MAOI) | 213 | ||
| Tricyclic Antidepressants (TCA) | 214 | ||
| Selective Serotonin (5-HT) Reuptake Inhibitors (SSRI) | 218 | ||
| Treatment of Major Depression | 220 | ||
| Mood Stabilisers | 224 | ||
| Psychomotor Stimulants | 226 | ||
| Psychotogenic Drugs | 227 | ||
| Drug Induced Psychiatric Syndromes | 230 | ||
| Chapter 15. Drug Therapy of Parkinsonism and Other Neurodegenerative Disorders | 231 | ||
| Drug Therapy | 232 | ||
| Management of Parkinsonism | 238 | ||
| Drug Therapy of Other Extrapyramidal Syndromes | 241 | ||
| Drug-induced Extrapyramidal Reactions (EPR) | 241 | ||
| Motor Neuron Disease (MND) Drug Therapy | 242 | ||
| Drugs and Memory | 242 | ||
| Multiple Sclerosis (MS) | 243 | ||
| SECTION III: Local Anaesthetics | 245 | ||
| Chapter 16. Cocaine, Procaine and Other Synthetic Local Anaesthetics | 245 | ||
| SECTION IV: Autonomic Nervous System | 251 | ||
| Chapter 17. General Considerations | 251 | ||
| Distribution of Parasympathetic Nervous System | 252 | ||
| Distribution of Sympathetic Nervous System | 253 | ||
| Enteric Nervous System (ENS) | 254 | ||
| Neurohumoral Transmission | 254 | ||
| Neurohumoral Transmitters | 255 | ||
| Neurotransmitter Uptake Mechanisms and Drugs | 259 | ||
| Chapter 18. Adrenergic Agonists and Antagonists | 262 | ||
| Catecholamines | 262 | ||
| Noncatecholamines | 273 | ||
| Noncatecholamines Mainly Used as Vasopressor Agents | 275 | ||
| Nasal Decongestants | 276 | ||
| Selective α2 Receptor Stimulants | 277 | ||
| Selective β2 Receptor Stimulants | 277 | ||
| Anorectic Sympathomimetic Drugs | 277 | ||
| Miscellaneous Compounds | 277 | ||
| Sympathetic Blocking Drugs | 277 | ||
| Adrenergic Receptor Blockers | 277 | ||
| Chapter 19. Cholinergic Drugs | 286 | ||
| Esters of Choline | 286 | ||
| Cholinomimetic Alkaloids | 290 | ||
| Cholinesterase Inhibitors | 290 | ||
| Organophosphorus Compound (OPC) Poisoning | 296 | ||
| Chapter 20. Muscarinic Receptor Blocking Drugs; Pharmacotherapy of Bladder Dysfunction | 299 | ||
| Belladonna Alkaloids | 299 | ||
| Synthetic and Semisynthetic Atropine Substitutes | 304 | ||
| Bladder Dysfunction – Pharmacology | 305 | ||
| Chapter 21. Ganglion Stimulating and Blocking Drugs | 308 | ||
| Ganglion Blocking Agents | 312 | ||
| Chapter 22. Skeletal Muscle Relaxants | 313 | ||
| Centrally Acting Skeletal Muscle Relaxants | 313 | ||
| Peripherally Acting Skeletal Muscle Relaxants | 316 | ||
| Drugs Acting Directly on Skeletal Muscle | 321 | ||
| SECTION V. Other Biogenic Amines and Polypeptides | 322 | ||
| Chapter 23. Histamine and Antihistaminic Drugs | 322 | ||
| Histamine, Anaphylaxis and Allergy | 326 | ||
| H1 Receptor Antagonists | 327 | ||
| H2 Receptor Antagonists | 332 | ||
| H3 and H4 Receptors | 332 | ||
| Chapter 24. 5-Hydroxytryptamine (Serotonin), its Agonists and Antagonists; and Treatment of Migraine | 333 | ||
| Pharmacotherapy of Migraine | 341 | ||
| Chapter 25. Angiotensin, Kinins, Leukotrienes, Prostaglandins and Cytokines | 344 | ||
| Kinins | 345 | ||
| Leukotrienes (LTs) | 346 | ||
| Prostaglandins (PGs) | 347 | ||
| Cytokines | 351 | ||
| SECTION VI: Drugs Used in Respiratory Disorders | 355 | ||
| Chapter 26. Pharmacotherapy of Cough | 355 | ||
| Pharyngeal Demulcents | 357 | ||
| Expectorants | 357 | ||
| Central Cough Suppressants | 358 | ||
| Peripherally Acting Agents | 359 | ||
| Other Antitussives | 359 | ||
| Mucolytic Agents | 360 | ||
| Chapter 27. Pharmacotherapy of Bronchial Asthma, COPD and Rhinitis | 361 | ||
| Drug Therapy During an Acute Attack | 365 | ||
| Prevention of Acute Attacks | 367 | ||
| Leukotriene Modifiers | 368 | ||
| Treatment of Chronic Persistent Asthma | 369 | ||
| Severe Acute Asthma (Status Asthmaticus) - Treatment | 373 | ||
| COPD – Management | 374 | ||
| Treatment of Acute Respiratory Failure | 376 | ||
| Surfactants and the Respiratory Distress Syndrome | 377 | ||
| Drug Therapy of Rhinitis | 377 | ||
| SECTION VII: Cardiovascular Drugs | 380 | ||
| Chapter 28. Pharmacotherapy of Cardiac Arrhythmias | 380 | ||
| Atrial fibrillation: Management | 396 | ||
| Drugs Used in the Treatment of Heart-Block | 397 | ||
| Chapter 29. Pharmacotherapy of Angina Pectoris, Acute MI and Peripheral Vascular Diseases | 398 | ||
| Methods of Assessing Coronary Circulation | 400 | ||
| Angina Pectoris | 400 | ||
| Drugs Used in Angina Pectoris | 401 | ||
| Potassium Channel Activators | 409 | ||
| Antiplatelet Drugs | 409 | ||
| Cytoprotectives | 409 | ||
| Treatment of Angina Pectoris | 410 | ||
| Acute Myocardial Infarction: Management | 412 | ||
| Drugs Used in the Treatment of Peripheral Vascular Disorders | 415 | ||
| Chapter 30. Pharmacotherapy of Hypertension, Pulmonary Hypertension and Orthostatic Hypotension | 416 | ||
| Drugs Acting Centrally | 419 | ||
| Ganglionic Blocking Agents | 421 | ||
| Adrenergic Neuron Blockers | 421 | ||
| Catecholamine Depletors | 422 | ||
| Adrenergic Receptor Blockers | 423 | ||
| Vasodilator Drugs | 426 | ||
| Potassium Channel Activators | 427 | ||
| Renin Inhibitors | 428 | ||
| Angiotensin Converting Enzyme Inhibitors (ACEI) | 428 | ||
| Angiotensin Receptor Blockers (ARB) | 430 | ||
| Aldosterone Antagonist | 431 | ||
| Thiazides as Antihypertensives | 431 | ||
| Miscellaneous Drugs | 432 | ||
| Hypertension – Therapy | 432 | ||
| Principles of Drug Therapy | 435 | ||
| Choice of Drug Therapy | 436 | ||
| Use of Drug Combinations | 436 | ||
| Management with Drugs | 436 | ||
| Hypertension in the Elderly | 439 | ||
| Hypertension in Pregnancy | 440 | ||
| Supportive Treatment of Hypertension | 441 | ||
| Treatment of Hypertensive Crises | 441 | ||
| Drug Induced Hypertension | 444 | ||
| Pulmonary Hypertension | 445 | ||
| Orthostatic hypotension | 446 | ||
| Chapter 31. Pharmacotherapy of Heart Failure | 447 | ||
| ACEI and Vasodilators in Heart Failure | 451 | ||
| Beta-adrenergic Blocking Agents in Heart Failure | 452 | ||
| Diuretics in Heart Failure | 453 | ||
| Aldosterone Antagonists in Heart Failure | 453 | ||
| Digitalis and Other Inotropic Agents in Heart Failure | 453 | ||
| Management of Acute LVF | 463 | ||
| Nonpharmacological Treatment of Heart Failure | 464 | ||
| Chapter 32. Pharmacotherapy of Shock | 465 | ||
| Whole Blood, Plasma and Plasma Fractions | 467 | ||
| Colloidal Plasma Expanders | 470 | ||
| Crystalloid Plasma Expanders | 472 | ||
| Cardiovascular Drugs in Shock | 473 | ||
| Treatment of Shock | 474 | ||
| SECTION VIII: Drugs Acting on Blood and Blood Forming Organs | 476 | ||
| Chapter 33. Drugs and Blood Coagulation | 476 | ||
| Antiplatelet Agents | 478 | ||
| Fast Acting Anticoagulants | 481 | ||
| Direct Thrombin Inhibitors | 484 | ||
| Slow Acting Anticoagulants | 485 | ||
| In Vitro Anticoagulants | 490 | ||
| Fibrinolytic Agents | 490 | ||
| Hemostatic Agents | 494 | ||
| Management of Acute Variceal Bleeding | 497 | ||
| Sclerosing Agents | 498 | ||
| Chapter 34. Drugs Effective in Iron Deficiency and Other Related Anemias | 499 | ||
| Iron Metabolism | 499 | ||
| Treatment of Iron Poisoning | 507 | ||
| Adjuvants to Iron Therapy | 508 | ||
| Erythropoietin (EPO) and Anemia | 508 | ||
| Chapter 35. Drugs Effective in Megaloblastic Anemias and Neutropenia | 509 | ||
| Drugs Used in Neutropenia | 517 | ||
| Drugs used in Thrombocytopenia | 518 | ||
| Chapter 36. Drug-Induced Blood Dyscrasias | 519 | ||
| SECTION IX: Water, Electrolytes and Drugs Affecting Renal Functions | 522 | ||
| Chapter 37. Water, Sodium, Potassium and Hydrion Metabolism | 522 | ||
| Water Metabolism | 524 | ||
| Sodium Metabolism | 526 | ||
| Sodium Depletion | 529 | ||
| Sodium Excess | 533 | ||
| Potassium Metabolism | 534 | ||
| Potassium Depletion and Hypokalemia | 535 | ||
| Hyperkalemia and Potassium Excess | 537 | ||
| Acidosis and Alkalosis | 538 | ||
| Acidosis | 540 | ||
| Alkalosis | 541 | ||
| Chapter 38. Nutritional Supplementation Therapy | 543 | ||
| Nutritional Requirements in Healthy Adults | 543 | ||
| Alterations in Nutritional Requirements in Acute Illness | 544 | ||
| Sequelae of Malnutrition | 545 | ||
| Assessment of Nutritional Status | 545 | ||
| Nutritional Supplementation: Aims and Indications | 545 | ||
| Enteral Nutrition | 545 | ||
| Parenteral Nutrition | 547 | ||
| Total Parenteral Nutrition (TPN) | 549 | ||
| Chapter 39. Diuretic and Anti-Diuretic Drugs | 552 | ||
| Diuretics | 555 | ||
| Osmotic Diuretics | 556 | ||
| Xanthines as Diuretics | 558 | ||
| Carbonic Anhydrase Inhibitors | 558 | ||
| Benzothiadiazines (Thiazides) | 560 | ||
| Loop Diuretics | 563 | ||
| Potassium Sparing Diuretics | 565 | ||
| Management of Edema | 567 | ||
| Complications of Diuretic Therapy | 570 | ||
| Acute Renal Failure (ARF) | 572 | ||
| Anti-diuretic Agents | 573 | ||
| Vasopressin ReceptorAntagonists | 575 | ||
| Drugs and Nephrotoxicity | 575 | ||
| SECTION X: Drugs Used in Disorders of the Gastrointestinal Tract | 577 | ||
| Chapter 40. Appetite Stimulants, Digestants, Antiflatulents, Appetite Suppressants and Hypolipidemic Agents | 577 | ||
| Digestants | 578 | ||
| Antiflatulents and Carminatives | 579 | ||
| Anorexiants and Treatment of Obesity | 579 | ||
| Atherosclerosis and Hyperlipidemia | 584 | ||
| Antihyperlipidemic Drugs | 588 | ||
| Chapter 41. Emetics, Drug Therapy of Vomiting, Vertigo and Diarrhoea | 594 | ||
| Emetics | 595 | ||
| Drug Therapy of Vomiting | 596 | ||
| Therapy of Vertigo and Dizziness | 600 | ||
| Drug Therapy of Diarrhoea | 601 | ||
| Chronic Diarrhoea | 608 | ||
| Chapter 42. Pharmacotherapy of Constipation | 610 | ||
| Anthraquinone Group | 613 | ||
| Irritant Oils | 613 | ||
| Miscellaneous Stimulant Laxatives | 614 | ||
| Osmotic Laxatives | 614 | ||
| Bulk Laxatives | 615 | ||
| Emollient Laxatives | 617 | ||
| 5-HT4 Receptor Agonists | 617 | ||
| Chloride Channel Activators | 617 | ||
| Constipation and Laxatives | 619 | ||
| Treatment of Hemorrhoids and Anal Fissure | 620 | ||
| Chapter 43. Pharmacotherapy of Peptic Ulcer Disease | 621 | ||
| Gastric Antacids | 625 | ||
| Non-Systemic Antacids | 625 | ||
| Systemic Antacids | 627 | ||
| Antacid Therapy | 627 | ||
| Antisecretory Agents | 628 | ||
| Mucosal Protective Drugs | 631 | ||
| Management of Peptic Ulcer | 632 | ||
| SECTION XI: Oxytocics and Uterine Relaxants | 636 | ||
| Chapter 44. Pharmacology of Ergot Alkaloids, Oxytocin, other Oxytocics and Uterine Relaxants | 636 | ||
| Ergot Alkaloids | 636 | ||
| Oxytocin | 638 | ||
| Other Oxytocics | 640 | ||
| Uterine Relaxants (Tocolytics) | 642 | ||
| SECTION XII: Chemotherapy | 644 | ||
| Chapter 45. Sulfonamides, Trimethoprim, Cotrimoxazole, Nitrofurans and Quinolones | 644 | ||
| Sulfonamides | 647 | ||
| Inflammatory Bowel Disease - Drug Therapy | 652 | ||
| Cotrimoxazole | 654 | ||
| Nitrofurans | 656 | ||
| Quinolones | 657 | ||
| Chapter 46. Penicillins and Other Antibiotics Effective Mainly Against Gram Positive Organisms | 661 | ||
| Semisynthetic Penicillins | 670 | ||
| Beta lactamase Inhibitors | 674 | ||
| Macrolides | 675 | ||
| Lincosamide Antibiotics | 678 | ||
| Glycopeptide Antibiotics | 679 | ||
| Miscellaneous Antibiotics | 679 | ||
| Streptogramins | 680 | ||
| Oxazolidinones | 681 | ||
| Chapter 47. Aminoglycosides and Other Antibiotics Effective Mainly Against Gram Negative Organisms | 682 | ||
| Non-aminoglycoside Agents | 687 | ||
| Monobactams | 688 | ||
| Chapter 48. Antibiotics Effective Against Both Gram Positive and Gram Negative Organisms | 689 | ||
| Cephalosporins | 689 | ||
| Carbapenems | 694 | ||
| Rifamycins | 694 | ||
| Drug Therapy of Bacterial Meningitis | 696 | ||
| Chapter 49. Tetracyclines and Chloramphenicol | 697 | ||
| Tetracyclines | 697 | ||
| Semisynthetic Tetracyclines | 700 | ||
| Chloramphenicol | 703 | ||
| Pharmacotherapy of Bacillary Dysentery | 706 | ||
| Pharmacotherapy of Chronic Bronchitis | 706 | ||
| Chapter 50. Antifungal Agents | 708 | ||
| Azole Derivatives | 711 | ||
| Echinocandins | 714 | ||
| Chapter 51. General Principles of Chemotherapy of Infections | 715 | ||
| Selection of Antimicrobial Agent | 715 | ||
| Antimicrobial Combinations | 720 | ||
| Antimicrobial Prophylaxis | 722 | ||
| Microbial Drug Resistance | 723 | ||
| Dangers of Antimicrobial Therapy | 725 | ||
| Misuse of Antimicrobial agents | 726 | ||
| Chapter 52. Chemotherapy of Urinary Tract Infections | 727 | ||
| Drug Therapy of UTI | 729 | ||
| Treatment of Lower UTI | 732 | ||
| Treatment of Upper UTI | 734 | ||
| Antimicrobial Prophylaxis | 735 | ||
| Chapter 53. Chemotherapy of Sexually Transmitted Diseases | 736 | ||
| Drug Therapy of Syphilis | 736 | ||
| Drug Therapy of Gonorrhea | 739 | ||
| Drug Therapy of Non-Gonococcal Urethritis (NGU) | 740 | ||
| Drug Therapy of Lymphogranuloma Venereum | 740 | ||
| Drug Therapy of Chancroid | 741 | ||
| Drug Therapy of Granuloma Inguinale | 741 | ||
| Vaginitis – Drug Therapy | 741 | ||
| SECTION XIII: Drugs Used in Endocrine Disorders | 860 | ||
| Chapter 63. Anterior Pituitary Hormones | 860 | ||
| Endocrine Physiology-Introduction | 860 | ||
| The Pituitary Gland | 865 | ||
| Chapter 64. Thyroid Hormones and Antithyroid Drugs | 870 | ||
| Treatment of Myxedema Coma | 877 | ||
| Iodine and the Endemic Goitre | 877 | ||
| Antithyroid Drugs | 877 | ||
| Pharmacotherapy of Hyperthyroidism | 881 | ||
| Thyrotoxic Crisis – Treatment | 883 | ||
| Iodine-Containing ContrastMedia | 884 | ||
| Chapter 65. Pancreatic Hormones, Antidiabetic Drugs and Pharmacotherapy of Diabetes Mellitus | 885 | ||
| Non-Insulin Antidiabetic Drugs | 897 | ||
| Oral Antidiabetic Agents | 898 | ||
| Parenteral Non-InsulinAntidiabetic Agents | 905 | ||
| Pharmacotherapy of Diabetes Mellitus | 906 | ||
| Management of Emergencies in the Diabetic | 915 | ||
| Hyperglycemic Agents | 917 | ||
| Sweetening Agents | 919 | ||
| Chapter 66. Adrenal Cortical Steroids | 920 | ||
| Adrenocorticotropin | 920 | ||
| Hormones of the Adrenal Cortex | 922 | ||
| Glucocorticoids and Mineralocorticoids | 923 | ||
| Adrenal Function Tests | 937 | ||
| Chapter 67. Gonadotropins, Estrogens and Progestins | 938 | ||
| Gonadotropins | 943 | ||
| Placental Hormones | 947 | ||
| Estrogens | 947 | ||
| Progesterone and Other Progestins | 955 | ||
| Chapter 68. Antifertility Agents and Ovulation Inducing Drugs | 962 | ||
| Estrogen-Progestin Combination Pill | 964 | ||
| Progestins Alone as Contraceptives | 970 | ||
| Antiestrogenic Agents | 971 | ||
| Injectable Contraceptives | 971 | ||
| Antiprogestins | 973 | ||
| Postcoital Contraception | 974 | ||
| Male Contraception | 974 | ||
| Medical Termination of Pregnancy (MTP) | 975 | ||
| Ovulation Inducing Drugs | 976 | ||
| Antigonadotropic Compounds | 978 | ||
| Chapter 69. Androgens, Anabolic Steroids and Antiandrogens | 980 | ||
| Erectile Dysfunction | 984 | ||
| Anabolic Steroids | 986 | ||
| Antiandrogens | 987 | ||
| Management of Hirsutism | 988 | ||
| Benign Prostatic Hyperplasia | 989 | ||
| Chapter 70. Calcium, Phosphorus, Fluoride and Magnesium Metabolism; Parathyroid Hormone and Vitamin D; Treatment of Osteoporosis | 991 | ||
| Phosphorus Metabolism | 997 | ||
| Osteoporosis – Management | 1008 | ||
| Fluoride | 1010 | ||
| Magnesium Metabolism | 1011 | ||
| SECTION XIV: Drugs Used in Common Skin and Eye Disorders | 1013 | ||
| Chapter 71. Pharmacotherapy of Common Skin Disorders and Skin Protectives | 1013 | ||
| Pharmacotherapy of Common Skin Disorders and Skin Protectives | 1013 | ||
| Principles of Drug Application | 1014 | ||
| Vehicles and Formulations | 1015 | ||
| Choice of Preparation | 1016 | ||
| Keratolytic Agents | 1017 | ||
| Drug Therapy of Bacterial and Viral Skin Infections | 1017 | ||
| Drug Therapy of Fungal Skin Infections | 1018 | ||
| Dandruff and Seborrhoeic Dermatitis | 1020 | ||
| Drug Therapy of Scabies and Pediculosis | 1021 | ||
| Drug Therapy of Acne Vulgaris | 1023 | ||
| Drug Therapy of Allergic Skin Disorders | 1026 | ||
| Drug Therapy of Psoriasis | 1027 | ||
| Drug Therapy of Alopecia | 1030 | ||
| Drugs Affecting Skin Pigmentation | 1031 | ||
| Sunscreens and Barrier Preparations | 1033 | ||
| Cosmetics, Tooth Powders and Dermal Fillers | 1033 | ||
| Anhidrotics and Deodorants | 1034 | ||
| Drug-Induced Skin Disorders | 1035 | ||
| Chapter 72. Ocular Pharmacology | 1037 | ||
| Antimicrobial Agents | 1040 | ||
| Glucocorticoids in Eye\r | 1041 | ||
| Antihistaminics and Mast Cell Stabilisers | 1042 | ||
| Mydriatics and Miotics | 1042 | ||
| Drug Therapy of Glaucoma | 1042 | ||
| Immunosuppressives and Antimitotic Drugs | 1044 | ||
| Local Anaesthetics | 1045 | ||
| Diagnostic Agents | 1045 | ||
| Miscellaneous Agents | 1045 | ||
| Drug Induced Ocular Toxicity | 1045 | ||
| SECTION XV: Immunopharmacology | 1046 | ||
| Chapter 73. General Considerations: Vaccines and Antisera | 1046 | ||
| Active Immunisation | 1050 | ||
| Passive Immunisation | 1056 | ||
| Drug Therapy of Scorpion Sting | 1060 | ||
| Chapter 74. Immunoglobulins, Monoclonal antibodies, Immunosuppressants and Immunomodulators | 1062 | ||
| Monoclonal Antibodies (mAb) in Therapeutics | 1064 | ||
| Immunosuppressants | 1066 | ||
| Immunostimulants and Immunomodulators | 1068 | ||
| SECTION XVI: Miscellaneous | 1070 | ||
| Chapter 75. Pharmacotherapy of Gout, Rheumatoid Arthritis and Osteoarthritis | 1070 | ||
| Drugs Used During Acute Stage | 1071 | ||
| Drugs Used in Long Term Therapy of Gout | 1073 | ||
| Xanthine Oxidase Inhibitors | 1073 | ||
| Uricosuric Drugs | 1074 | ||
| Pharmacotherapy of Rheumatoid Arthritis (RA) | 1075 | ||
| Osteoarthritis (OA) | 1081 | ||
| Chapter 76. Metals and Their Antagonists | 1083 | ||
| Heavy Metal Antagonists | 1087 | ||
| Chapter 77. Gases: Therapeutic and Toxic | 1092 | ||
| Therapeutic Gases | 1092 | ||
| Toxic Gases | 1098 | ||
| Chapter 78. Enzymes in Therapy | 1101 | ||
| Chapter 79. Vitamins and Antioxidants | 1104 | ||
| Fat Soluble Vitamins | 1105 | ||
| Water Soluble Vitamins | 1108 | ||
| Antioxidants | 1115 | ||
| Chapter 80. Drugs, Pregnancy and the Infant | 1117 | ||
| Pharmacokinetics During Pregnancy | 1117 | ||
| Drugs, the Fetus and the Newborn | 1118 | ||
| Effects of Drugs on Pregnancy | 1120 | ||
| Teratogenicity | 1120 | ||
| Drug-Prescribing During Pregnancy | 1123 | ||
| Breast Feeding and Drugs | 1126 | ||
| APPENDIX: Guide to Further Reading | 1128 | ||
| Index | 1129 |